Amphastar Pharmaceuticals (AMPH) to Release Quarterly Earnings on Thursday

Key Points

• Amphastar Pharmaceuticals is expected to announce its Q2 2025 earnings on August 6th, with analysts predicting earnings of $0.71 per share and revenue of $173.42 million.
• The company's shares opened at $21.67, with a market cap of $1.02 billion and a PE ratio of 7.85.
• Analyst reports indicate a predominance of "hold" ratings, with a consensus price target of $32.33 and notable reductions in target prices from various firms.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) is projected to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of $0.71 per share and revenue of $173.42 million for the quarter.

Amphastar Pharmaceuticals Stock Performance

AMPH traded up $0.26 on Friday, hitting $21.21. 440,154 shares of the company's stock were exchanged, compared to its average volume of 454,819. The firm has a market cap of $999.84 million, a PE ratio of 7.68 and a beta of 0.76. Amphastar Pharmaceuticals has a twelve month low of $20.39 and a twelve month high of $53.96. The stock has a fifty day moving average of $23.71 and a two-hundred day moving average of $26.69. The company has a current ratio of 2.95, a quick ratio of 2.02 and a debt-to-equity ratio of 0.80.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on AMPH shares. Wells Fargo & Company dropped their price objective on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Finally, JPMorgan Chase & Co. restated a "neutral" rating and issued a $30.00 price target (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $32.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Intech Investment Management LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 43.0% in the first quarter. Intech Investment Management LLC now owns 60,289 shares of the company's stock valued at $1,748,000 after acquiring an additional 18,133 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Amphastar Pharmaceuticals by 82.0% during the first quarter. AQR Capital Management LLC now owns 53,638 shares of the company's stock worth $1,555,000 after buying an additional 24,167 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Amphastar Pharmaceuticals by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company's stock worth $652,000 after buying an additional 613 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.